Grifols

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Grifols and buy or sell other stocks, ETFs, and their options commission-free!

About GRFS

Grifols SA is a global specialty plasma therapeutics company that engages in the development, manufacturing, and distribution of a broad range of biological medicines based on plasma-derived proteins. It operates through the following segments: Biopharma, Diagnostic, Bio Supplies, and Others. 

CEO
Jose Ignacio Abia Buenache
CEOJose Ignacio Abia Buenache
Employees
25,258
Employees25,258
Headquarters
Barcelona, Catalonia
HeadquartersBarcelona, Catalonia
Founded
1909
Founded1909
Employees
25,258
Employees25,258

GRFS Key Statistics

Market cap
7.18B
Market cap7.18B
Price-Earnings ratio
10.14
Price-Earnings ratio10.14
Dividend yield
2.90%
Dividend yield2.90%
Average volume
1.01M
Average volume1.01M
High today
$8.12
High today$8.12
Low today
$7.84
Low today$7.84
Open price
$8.11
Open price$8.11
Volume
442.84K
Volume442.84K
52 Week high
$10.84
52 Week high$10.84
52 Week low
$6.96
52 Week low$6.96

GRFS News

Simply Wall St 22h
Is Grifols A Bargain On Mixed Half Year Earnings? - simplywall.st

...

Is Grifols A Bargain On Mixed Half Year Earnings? - simplywall.st
TipRanks 6d
Grifols Reshapes Board and Committee Leadership After Director Resignation

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.